Although imatinib remains the gold standard for first-line treatment of chronic myeloid
leukemia (CML), increasing recognition of imatinib resistance and intolerance has led to the …

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near
normal life-expectancy. However, since the majority of patients will need to remain on …

All available data from ongoing studies of second-generation tyrosine kinase inhibitors
(TKIs) for treatment of patients with newly diagnosed chronic myeloid leukemia in chronic …

Chronic myeloid leukemia (CML) is a progressive and often fatal myeloproliferative
neoplasm. The hallmark of CML is an acquired chromosomal translocation known as the …

Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …

Abstract Purpose of Review Over the past two decades, the introduction of tyrosine kinase
inhibitors (TKIs) has transformed the treatment of chronic myeloid leukemia (CML). With four …

The clinical outcome for patients with chronic myelogenous leukemia (CML) has changed
dramatically in the past 15 years. This has been due to the development of tyrosine kinase …

The advent of imatinib has dramatically improved outcomes in patients with chronic
myelogenous leukemia (CML). It has become the standard of care for all patients with newly …

Background Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem
cells. The tyrosine kinase inhibitor (TKI) imatinib was the first targeted therapy licensed for …